醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床研究  

Clinical trial of Xingnaojing injection combined with atorvastatin calcium in the treatment of acute cerebral hemorrhage

作　　者：何玉清[1] 魏立平[1] 李文波[1] 张耀慧[1] 庞红立[1] 严澎[1] 

机构地区：[1]洛阳市中心医院神经内科,河南洛阳471009

出　　处：《中国临床药理学杂志》2017年第9期774-777,共4页The Chinese Journal of Clinical Pharmacology

基　　金：河南省科技厅科技攻关基金资助项目(112102310173)

摘　　要：目的观察醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床疗效及安全性。方法 68例急性脑出血患者随机分为对照组34例与试验组34例,2组均给予常规治疗以及对症治疗。对照组给予阿托伐他汀钙胶囊20 mg,每日1次,口服,试验组在对照组的基础上给予醒脑静注射液20 m L,每日2次,静脉滴注。2组均治疗21 d。比较2组患者的临床疗效、治疗前后血清C反应蛋白(CRP)、白细胞介素-1β(IL^(-1)β)、肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)、丙二醛(MDA)和超氧化物歧化酶(SOD)水平及药物不良反应发生情况。结果治疗后,对照组临床总有效率为76.47%(26/34例),试验组为94.12%(32/34例,P<0.05)。治疗后,试验组和对照组血清CRP分别为(3.72±0.86),(5.18±0.51)mg·L^(-1),IL^(-1)β分别为(4.02±0.41),(5.48±0.58)ng·L^(-1),TNF-α分别为(19.47±2.13),(29.59±3.04)μg·L^(-1),NO分别为(3.03±0.34),(4.11±0.42)ng·L^(-1),MDA分别为(6.04±0.61),(7.17±0.76)μmol·m L^(-1),SOD分别为(162.01±16.34),(142.63±14.64)U·m L^(-1)(P<0.05)。试验组药物不良反应有头痛、恶心、皮疹,药物不良反应发生率为8.82%(3/34例),对照组药物不良反应有头痛、视物模糊、恶心、失眠,药物不良反应发生率为14.70%(5/34例,P>0.05)。结论醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床疗效显著,安全性高。Objective To evaluate the clinical efficacy and safety of Xingnaojing injection combined with atorvastatin calcium in the treatment of acute cerebral hemorrhage. Methods A total of 68 cases with acute cerebral hemorrhag were divided into control group and treatment group, each group 34 cases. Patients in both groups were given regular treat- ment. Patients in control group were orally given atorvastatin calcium capsules 20 mg, once a day. Patients in treatment group were received Xingnaojing injection 20 mL by intravenous drip, twice a day on the basis of control group. All patients were treated for 21 d. The clinical efficacy, C reactive protein （CRP） , intcrleukin - 1β （ IL - 1β ）, tumor necrosis factor - α （ TNF - α）, nitric oxide （ NO ）, malondialdehyde （ MDA ）, superoxide dismutase （SOD） and adverse drug reactions were comparedin two groups. Results The clinical efficacy in treatment group was 94. 12% （32/34）, had significant difference with that in control group, which was 76.47% （26/34, P 〈 0. 05 ）. After treatment, the serum CRP of treatment group and control group were （3.72 ±0. 86）, （5.18 ±0. 51）mg · L^-1, IL- 1β were （4. 02 ±0. 41）, （5.48 ±0. 58）ng · L^-1 , TNF-awere （19.47 ±2.13）, （29.59 ±3.04） μg·L^-1, NO were （3.03±0.34）, （4. 11±0.42） ng · L^-l, MDAwere （6.04±0.61）, （7.17±0.76） μmol· mL^-l, SOD were （162.01±16.34）, （142.63 ±14.64） U · mL^-l （p 〈 0. 05 ）. In treatment group, patients had headache, nausea, rash, incidence of adverse drug reactions was 8.82% （3/34 cases）. In control group, patients had headache, vision fuzzy, nausea, insomnia, incidence of adverse drug reactions was 14. 70% （5/34 cases, P 〉 0. 05 ）. Conclusion Xingnaojing injection combined with atorvastatin calcium in the treatment of acute cerebral hemorrhag was effective with high safety.

关 键 词：醒脑静注射液 阿托伐他汀钙胶囊 急性脑出血 白细胞介素-1Β 超氧化物歧化酶 

分 类 号：R973[医药卫生—药品]